Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

a preliminary proof-of-concept for an all oral, nucleotide combination regimen."Calendar Year 2011 Anticipated Milestones:-- Pharmasset expects to report SVR12 data from its ongoing phase 2b trial with PSI-7977 in HCV genotype 2/3 patients in the second quarter of 2011

-- Pharmasset expects to report the 12 week interim analysis from its PSI-7977 Phase 2b genotype 1 arms in the second quarter of 2011

-- Pharmasset expects to initiate a 24 week Phase 2b trial with PSI-7977 in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2 study with PSI-7977 and PSI-938 in mid-2011

-- Pharmasset plans to file an IND for PSI-661 in the first quarter of 2011 and to initiate a phase 1 trial in the second quarter of 2011

-- Roche expects to initiate INFORM-SVR with RG7128 and RG7227 in the first quarter of 2011

-- Roche expects to initiate a phase 2 study with RG7128 in HCV genotype 2/3 patients in the first half of 2011

-- Roche expects to initiate a phase 3 program with RG7128 in 2011

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strate
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary ... SAM Junctional Tourniquet.  Photo - ... Products announced today that it has begun notifying ... potential issue with a clip used to secure ... of the SAM Junctional Tourniquet (SJT).  The company ...
(Date:8/29/2014)... PARK, Calif. , Aug. 29, 2014 ... Medical as CEO and member of the Board of ... decades of medical device development and commercialization experience, including ... field. Mr. Engelson previously served as a Partner of ... as President and CEO of two Foundry start-ups. Mr. ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... 2011 CRC Health Group, the nation,s largest ... today announced the successful acquisition of North Carolina,s ... Solutions, comprised of two facilities located in Asheville ... program by the U.S. Department of Health and ...
... Inc., a leader in medical billing and practice management for ... clients are highly satisfied with its services, according to the ... percent of those surveyed said they would recommend Orion to ... physician groups, laboratories, imaging centers and other healthcare provider clients ...
Cached Medicine Technology:CRC Health Group Announces Acquisition of North Carolina's Mountain Health Solutions 2Orion HealthCorp Gets High Marks From Clients 2
(Date:9/1/2014)... 01, 2014 Parties involved in federally-filed ... the litigation’s status conference in September, where issues related ... in the Eastern District of Pennsylvania, Bernstein Liebhard LLP ... conferences posted on the Court’s website, the meeting is ... 10:00 a.m. This is the latest of several Tylenol ...
(Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... US FDA announced on August 28, that specific lots ... (Class I) as the device may reverse directions ... Synthes Craniomaxillofacial (CMF) Distraction System is an implant used ...
(Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
(Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4
... the Queen Silvia Children,s Hospital has developed a method that ... a CT scan while still obtaining good image quality, reveals ... an advanced form of X-ray examination which generates images that ... the dose of radiation is lowered too far, however, the ...
... , MONDAY, April 4 (HealthDay News) -- People with ... new study suggests. It also found that a decrease ... abuse and mood disorders. Researchers analyzed data from nearly ... the U.S. National Epidemiologic Survey of Alcohol and Related Conditions. ...
... Eran Shor, working in collaboration with researchers from Stony ... of premature mortality by 63 per cent. Shor reached ... people in 15 (mainly western) countries, over the last ... in spite of expectations that a better health-care system ...
... HealthDay Reporter , MONDAY, April 4 (HealthDay News) -- Heavy ... metabolism of alcohol may face a higher risk than others ... a certain genetic variant and drinking roughly three ... markedly increase the risk of "non-cardia gastric cancer," a study ...
... 2011) The gender gap among United States Medical ... surgery is shrinking, according to study results published in ... American College of Surgeons . These findings align with ... medical students. The study found a 22 percent ...
... Goodwin HealthDay Reporter , MONDAY, April ... use of most medications for treating autism in ... risperidone and aripiprazole that have shown success in ... new study shows. However, anti-psychotics can have ...
Cached Medicine News:Health News:Safer CT scanning for children developed at the Queen Silvia Children's Hospital 2Health News:Poverty Linked to Anxiety, Mood Disorders 2Health News:Men who lose their jobs at greater risk of dying prematurely 2Health News:Heavy Beer Drinking, Genetics May Raise Risk of Stomach Cancer 2Health News:Heavy Beer Drinking, Genetics May Raise Risk of Stomach Cancer 3Health News:More women medical students select general surgery and continue to close the gender gap 2Health News:Evidence Weak to Support Many Medications for Autism: Study 2Health News:Evidence Weak to Support Many Medications for Autism: Study 3Health News:Evidence Weak to Support Many Medications for Autism: Study 4
... West Nile Virus IgG DxSelect is ... West Nile virus in human,serum. In ... Nile Virus,IgM Capture DxSelect, the test ... of meningioencephalitis, as an aid in ...
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Conducting disposable filter-tips....
Medicine Products: